Item 5.02 Departure of Directors or Certain Officers; Election of Directors;


          Appointment of Certain Officers; Compensatory Arrangements of Certain
          Officers.

On January 23, 2023, DarioHealth Corp. (the "Company"), through its wholly owned subsidiary Labstyle Innovation Ltd., executed a Termination of Employment and Separation Agreement (the "Agreement") with Dror Bacher, the Company's Chief Operating Officer, pursuant to which Mr. Bacher's position as Chief Operating Officer was terminated with immediate effect.

Pursuant to the terms of the Agreement, the Company agreed to retain Mr. Bacher as a member of its advisory board. The Company also agreed to pay Mr. Bacher, in lieu of his notice period and accrued vacation, a reduced monthly salary of 42,137 NIS ($12,504) for the period from February 1, 2023 through May 31, 2025. In addition, the Company agreed, subject to the approval of the Company's Compensation Committee, to issue Mr. Bacher 75,000 shares of restricted stock which shall vest on a quarterly basis from the date of grant through December 31, 2024.

The foregoing description of the terms of the Agreement are not intended to be complete and is qualified in its entirety by reference to the Agreement, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.






(d) Exhibits




  10.1     Termination of Employment and Separation Agreement dated January 23, 2023
         by and between Dror Bacher and Labstyle Innovation Ltd.
104      Cover Page Interactive Data File (embedded within the Inline XBRL document).

© Edgar Online, source Glimpses